APLS - アペリス・ファ―マシュ―ティカルズ (Apellis Pharmaceuticals Inc.) アペリス・ファ―マシュ―ティカルズ

 APLSのチャート


 APLSの企業情報

symbol APLS
会社名 Apellis Pharmaceuticals Inc (アペリス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アペリス・ファーマスーティカルズ(Apellis Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は自己免疫および炎症性疾患の治療化合物の発見・開発に焦点を当てる。同社のリード化合物は補体カスケードにある中心タンパク質である補体成分3(C3)を阻害するように設計される。同社は皮膚下の組織への注射である皮下注射による発作性夜間ヘモグロビン尿症(PNH)の治療用APL-2を開発中である。同社は眼内への注射である硝子体内注射により、地図状萎縮(GA)および加齢黄斑変性(AMD)の治療用APL-2を開発中である。同社は吸入投与による慢性閉塞性肺疾患(COPD)の治療用APL-1を開発中である。   アペリス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、免疫系の構成要素である補体系の阻害を介して、補体カスケ―ドの中心タンパク質であるC3のレベルで、疾患を治療する化合物の開発に従事する。同社は、補体依存性の自己免疫疾患や炎症性疾患を治療するために開発する。本社所在地はケンタッキ―州クレストウッド。   
本社所在地 6400 Westwind Way Suite A Crestwood KY 40014 USA
代表者氏名 Gerald Chan ジェラルドチャン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 502-241-4114
設立年月日 40057
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 39人
url www.apellis.com
nasdaq_url https://www.nasdaq.com/symbol/apls
adr_tso
EBITDA EBITDA(百万ドル) -84.50572
終値(lastsale) 16.01
時価総額(marketcap) 899411765.24
時価総額 時価総額(百万ドル) 888.73790
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 661.65977
当期純利益 当期純利益(百万ドル) -84.89977
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Apellis Pharmaceuticals Inc revenues was not reported. Net loss increased from $21.2M to $55.1M. Higher net loss reflects Research and Development increase from $17.7M to $44.9M (expense) General and Administrative increase from $3.5M to $10M (expense) Interest income (expense) net increase from $0K to $83K (expense).

 APLSのテクニカル分析


 APLSのニュース

   Healthcare hedge fund Rhenman still buoyant on sector, as flagship strategy advances in January  2021/02/09 16:32:57 Hedgeweek
Healthcare hedge fund Rhenman still buoyant on sector, as flagship strategy advances in January Submitted By Hugh Leask | 09/02/2021 - 4:32pm The healthcare sector can expect a “reasonably stable political environment” this year, according to healthcare-focused specialist hedge fund Rhenman & Partners Asset Management, whose buoyant stance comes after its flagship strategy finished last month in positive territory. The firm’s flagship Rhenman Healthcare Equity Long/Short hedge fund rose 1.32 per cent in its main euro share class last month, as its SEK-denominated tranche grew 1.81 per cent. The strategy – which trades a range of small, medium and large pharmaceuticals, biotechnology, medical technology and service company stocks – was able to generate profits across three of its four main areas of focus last month. But with health insurance stocks taking a beating in January, positions in service sector names proved a drag on performance, the firm said in a client update on Tuesday. Among the fund’s best performers in January was Teladoc Health, a large US telehealth and telemedicine provider, which has benefited from the rise in virtual healthcare during the coronavirus pandemic.
   Stifel Nicolaus Stick to Their Buy Rating for Apellis Pharmaceuticals Inc By Investing.com  2021/01/21 09:08:42 Investing.com
Stifel Nicolaus Stick to Their Buy Rating for Apellis Pharmaceuticals Inc
   Raymond James Stick to Their Buy Rating for Apellis Pharmaceuticals Inc By Investing.com  2021/01/08 16:52:13 Investing.com
Raymond James Stick to Their Buy Rating for Apellis Pharmaceuticals Inc
   Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock  2021/01/07 11:55:00 GlobeNewswire
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted…
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   Stifel Nicolaus Stick to Their Buy Rating for Apellis Pharmaceuticals Inc By Investing.com  2021/01/21 09:08:42 Investing.com
Stifel Nicolaus Stick to Their Buy Rating for Apellis Pharmaceuticals Inc
   Raymond James Stick to Their Buy Rating for Apellis Pharmaceuticals Inc By Investing.com  2021/01/08 16:52:13 Investing.com
Raymond James Stick to Their Buy Rating for Apellis Pharmaceuticals Inc
   Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock  2021/01/07 11:55:00 GlobeNewswire
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted…
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   Oppenheimer Stick to Their Buy Rating for Apellis Pharmaceuticals Inc  2020/12/10 16:15:27 Investing.com
Oppenheimer Stick to Their Buy Rating for Apellis Pharmaceuticals Inc
   Global IgA Nephropathy Market To See Astonishing Growth By 2027|Merck KGaA, Reata Pharmaceuticals, Inc, AbbVie, Inc., Allergan., Apellis Pharmaceuticals, Amgen Inc  2020/09/30 18:04:26 OpenPR
Due to the pandemic, we have included a special section on the Impact of COVID 19 on the IgA Nephropathy Market which would mention How the Covid-19 is affecting the IgA Nephropathy Industry, Market Trends and Potential Opportunities
   Apellis Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference  2020/06/04 11:00:00 GlobeNewswire
WALTHAM, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3…
   Why Apellis Pharmaceuticals (APLS) Stock Might be a Great Pick  2020/04/07 14:01:00 Zacks Investment Research
Apellis Pharmaceuticals (APLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
   Mumbai based IPCA gets a shot in the arm as USFDA suspends import ban for key Covid-19 drug  2020/03/23 05:12:26 The Economic Times India
MUMBAI: IPCA labs, one of the largest supplier of anti malarial drug Chloroquine and the Rheumatoid Artharitis drug Hydroxychloroquine has got its import alert suspended as the USFDA by the USFDA made an exception to the company because of the possible rise in demand of these drugs arising out of the Covid-19 pandemic. "We wish to inform you that due to the shortage implications and/or medical necessity of certain drugs and finished products, the United States Food and Drug Administration (FDA) vide its e-mails dated 20th March, 2020 has made exception to the import alert for the Company's following Active Pharmaceutical Ingredients (APls) and finished products (Formulations)", IPCA said to stock exchanges. IPCA's shares on Friday's trade had closed 9% up at Rs 1371.According to the Centre for Disease Control USA, a study in China reported that chloroquine treatment of COVID-19 patients had clinical and virologic benefit versus a comparison group, and chloroquine was added as a recommended antiviral for treatment of COVID-19 in China.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.

 関連キーワード  (医薬品 米国株 アペリス・ファ―マシュ―ティカルズ APLS Apellis Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)